dr. ready on the benefit of pd-l1 inhibition in sclc
Published 5 years ago • 165 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:24
dr. lilenbaum on pd-l1 as a predictive biomarker for immunotherapy in lung cancer
-
2:40
dr. ready on promising treatment approaches in sclc
-
1:02
dr. gubens discusses the role of pd-l1 in patients with nsclc
-
1:55
dr. hirsch on value of pd-l1 testing in patients with lung cancer
-
5:03
pd-l1 less than 49%: available treatments
-
2:20
dr. john haanen on the role of pd-l1 in lung cancer
-
1:59
dr. david l. rimm on alternatives to pd-l1 to predict immunotherapy response in lung cancer
-
1:03
dr. barbara j. gitlitz on why pd-l1 is not a good biomarker for immunotherapy in lung cancer
-
2:07
dr. belani on pd-1 inhibitors for non-small cell lung cancer
-
2:01
dr. welsh on new understanding of regulating pd-l1 expression
-
3:50
pd-l1 expression in nsclc
-
10:20
pd-l1 testing in advanced lung cancer
-
4:52
targeting the immune system in non-small cell lung cancer
-
1:13
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
7:34
pd-l1 as a biomarker in squamous non-small cell lung cancer
-
0:56
dr. papadimitrakopoulou on role of immunotherapy in lung cancer
-
1:23
dr. liu on the potential of pembrolizumab in sclc
-
2:07
dr. chen on the impact of the pivotal impower133 trial on sclc
-
3:00
small-cell lung cancer: future directions in care